The FDA approved Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) as a subcutaneous (SC) treatment for adult patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer or early-stage HER-2 positive disease. The treatment combines 2 monoclonal antibodies in a single SC injection.
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf; Genentech) has been approved by the FDA as a subcutaneous (SC) treatment for adult patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer or early-stage HER-2 positive disease.
The treatment works by disrupting cancer cell growth through pertuzumab and trastuzumab binding to HER2. This approval comes on the heels of Phesgo’s efficacy and safety results from 500 patients enrolled in the FeDeriCa open label, multicenter, randomized trial that compared treatment with it with IV pertuzumab and IV trastuzumab.
In a statement, Genentech said it is the first time the company has combined 2 monoclonal antibodies in a single SC injection.
There are 2 phases of dosing. Phesgo’s initial dose contains pertuzumab 1200 mg, trastuzumab 600 mg, and hyaluronidase 30,000 units over 8 minutes. A second dose contains pertuzumab 600 mg, trastuzumab 600 mg, and hyaluronidase 20,000 units and is given every 3 weeks for 5 minutes.
There is a warning attached for women who are pregnant, as the treatment can harm the fetus or a newborn child. It addition, women who are thinking of becoming pregnant are advised that taking the combination treatment within 7 months of becoming pregnant is another risk factor for fetal harm.
Other warnings include those for heart failure and lung toxicity, both of which health care professionals (HCPs) and patients should be informed. In return, HCPs need to monitor using parameters similar to “those used with [intravenous (IV)] pertuzumab and IV trastuzumab,” noted the FDA’s press release touting Phesgo’s approval.
“Currently, most patients with HER2-positive breast cancer receive trastuzumab and pertuzumab at infusion centers. With a new administration route, Phesgo offers an out-patient option for patients to receive trastuzumab and pertuzumab,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research.
Pazdur, a 2019 Giants of Cancer Care® recipient for his community outreach, highlighted how continuing to account for the increased vulnerability of patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic necessitated the sped-up approval process. Phesgo’s application for FDA approval came in 4 months ahead of schedule.
Initial administration of Phesgo’s fixed-dose combination of pertuzumab and trastuzumab—the therapeutic ingredients which are identical to IV pertuzumab and IV trastuzumab—with hyaluronidase takes place in combination with chemotherapy:
A qualified HCP is allowed to continue the treatment in the home setting following completion of chemotherapy.
This latest approval for HER2-positive disease follows approvals of tucatinib (Tuksya, Seattle Genetics) in April and neratinib (Nerlynx, Puma Biotechnology) in February, both in the advanced or metastatic setting.
Adverse effects for Phesgo are alopecia, nausea, diarrhea, anemia, asthenia, worsening of chemotherapy-induced neutropenia, and anaphylaxis or hypersensitivity. These last 2 AEs call of discontinuation of Phesgo. Injection-site reactions are also possible due to it being an SC drug.
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More